Strs Ohio Purchases 15,848 Shares of Masimo Corporation $MASI

Strs Ohio raised its position in shares of Masimo Corporation (NASDAQ:MASI) by 39.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 55,983 shares of the medical equipment provider’s stock after acquiring an additional 15,848 shares during the period. Strs Ohio’s holdings in Masimo were worth $9,417,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of MASI. Durable Capital Partners LP bought a new position in shares of Masimo in the first quarter valued at approximately $187,528,000. Massachusetts Financial Services Co. MA increased its holdings in Masimo by 13.4% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,967,838 shares of the medical equipment provider’s stock valued at $327,842,000 after purchasing an additional 232,671 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Masimo in the first quarter valued at $25,830,000. Alyeska Investment Group L.P. increased its stake in shares of Masimo by 24.9% in the first quarter. Alyeska Investment Group L.P. now owns 722,534 shares of the medical equipment provider’s stock valued at $120,374,000 after buying an additional 143,899 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Masimo by 26.3% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 471,041 shares of the medical equipment provider’s stock valued at $79,239,000 after buying an additional 98,063 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on MASI shares. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Zacks Research lowered shares of Masimo from a “strong-buy” rating to a “hold” rating in a report on Friday, October 24th. Piper Sandler lifted their target price on Masimo from $200.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Finally, BTIG Research reissued a “buy” rating and issued a $198.00 target price on shares of Masimo in a research note on Thursday, September 11th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $194.60.

Masimo Price Performance

MASI opened at $140.65 on Friday. The company has a fifty day moving average price of $144.80 and a two-hundred day moving average price of $154.10. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. Masimo Corporation has a 52 week low of $133.70 and a 52 week high of $194.88. The firm has a market capitalization of $7.64 billion, a PE ratio of -16.51 and a beta of 1.28.

Masimo (NASDAQ:MASI) last released its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. The firm had revenue of $617.00 million during the quarter. As a group, analysts anticipate that Masimo Corporation will post 4.1 earnings per share for the current year.

Insider Activity

In related news, Director William R. Jellison bought 3,000 shares of the firm’s stock in a transaction dated Monday, August 11th. The stock was bought at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the transaction, the director owned 4,790 shares of the company’s stock, valued at $699,244.20. This represents a 167.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 9.70% of the company’s stock.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.